Literature DB >> 25043733

Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression.

Helena Domin1, Bernadeta Szewczyk1, Monika Woźniak1, Anika Wawrzak-Wleciał1, Maria Śmiałowska2.   

Abstract

The glutamatergic predominance in the excitatory-inhibitory balance is postulated to be involved in the pathogenesis of depression. Such imbalance may be induced by astrocyte ablation which reduces glutamate uptake and increases glutamate level in the synaptic cleft. In the present study, we tried to ascertain whether astroglial degeneration in the prefrontal cortex could serve as an animal model of depression and whether inhibition of glutamatergic transmission by the mGluR5 antagonist MTEP could have antidepressant potential. Astrocytic toxins l-or dl-alpha-aminoadipic acid (AAA), 100μg/2μl, were microinjected, bilaterally into the rat medial prefrontal cortex (PFC) on the first and second day of experiment. MTEP (10mg/kg) or imipramine (30mg/kg) were administered on the fifth day. Following administration of MTEP or imipramine the forced swim test (FST) was performed for assessment of depressive-like behavior. The brains were taken out for analysis on day eight. The astrocytic marker, glial fibrillary acidic protein (GFAP) was quantified in PFC by Western blot method and by stereological counting of immunohistochemically stained sections. Both l-AAA and dl-AAA induced a significant increase in immobility time in the FST. This effect was reversed by imipramine, which indicates depressive-like effects of these toxins. A significant decrease in GFAP (about 50%) was found after l-AAA. Both the behavioral and GFAP level changes were prevented by MTEP injection. The obtained results indicate that the degeneration of astrocytes in the PFC by l-AAA may be a useful animal model of depression and suggest antidepressant potential of MTEP.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Depression; Gliotoxin; MTEP; l-AAA; mGluR5 antagonist

Mesh:

Substances:

Year:  2014        PMID: 25043733     DOI: 10.1016/j.bbr.2014.07.019

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  13 in total

Review 1.  Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.

Authors:  Samuel A Barnes; Douglas J Sheffler; Svetlana Semenova; Nicholas D P Cosford; Anton Bespalov
Journal:  Biol Psychiatry       Date:  2018-03-09       Impact factor: 13.382

2.  Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.

Authors:  Ruin Moaddel; Michelle Shardell; Mohammed Khadeer; Jacqueline Lovett; Bashkim Kadriu; Sarangan Ravichandran; Patrick J Morris; Peixiong Yuan; Craig J Thomas; Todd D Gould; Luigi Ferrucci; Carlos A Zarate
Journal:  Psychopharmacology (Berl)       Date:  2018-08-16       Impact factor: 4.530

Review 3.  Astroglia Abnormalities in Post-stroke Mood Disorders.

Authors:  Tracey Singer; Sarah Ding; Shinghua Ding
Journal:  Adv Neurobiol       Date:  2021

4.  mGluR5 Facilitates Long-Term Synaptic Depression in a Stress-Induced Depressive Mouse Model.

Authors:  Xiangzhi Jiang; Wei Lin; Yuanyuan Cheng; Dongming Wang
Journal:  Can J Psychiatry       Date:  2019-09-16       Impact factor: 4.356

5.  Novel Glutamatergic Treatments for Severe Mood Disorders.

Authors:  Minkyung Park; Mark J Niciu; Carlos A Zarate
Journal:  Curr Behav Neurosci Rep       Date:  2015-10-09

6.  Emotional Impairment and Persistent Upregulation of mGlu5 Receptor following Morphine Abstinence: Implications of an mGlu5-MOPr Interaction.

Authors:  Panos Zanos; Polymnia Georgiou; Loreto Rojo Gonzalez; Susanna Hourani; Ying Chen; Ian Kitchen; Brigitte L Kieffer; Raphaelle Winsky-Sommerer; Alexis Bailey
Journal:  Int J Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 5.176

Review 7.  The Effects of Psychological Stress on Depression.

Authors:  Longfei Yang; Yinghao Zhao; Yicun Wang; Lei Liu; Xingyi Zhang; Bingjin Li; Ranji Cui
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

8.  Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence.

Authors:  Helena Domin; Bernadeta Szewczyk; Bartłomiej Pochwat; Monika Woźniak; Maria Śmiałowska
Journal:  Psychopharmacology (Berl)       Date:  2016-12-14       Impact factor: 4.530

9.  Decreased Glycogen Content Might Contribute to Chronic Stress-Induced Atrophy of Hippocampal Astrocyte volume and Depression-like Behavior in Rats.

Authors:  Yunan Zhao; Qiang Zhang; Xiao Shao; Liufeng Ouyang; Xin Wang; Kexuan Zhu; Lin Chen
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

Review 10.  Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.

Authors:  Brittany A Jaso; Mark J Niciu; Nicolas D Iadarola; Niall Lally; Erica M Richards; Minkyung Park; Elizabeth D Ballard; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.